Apollo Therapeutics Secures $226.5 Million in Funding to Accelerate Transformative Therapeutic Pipeline Expansion

We are thrilled to announce that Apollo Therapeutics has successfully raised $226.5 million in funding, a significant milestone that will accelerate our mission to bring innovative therapeutic options to patients around the world. As a pioneering biopharmaceutical company, Apollo Therapeutics is dedicated to advancing our robust pipeline of transformative treatment programs, which are rooted in groundbreaking discoveries made in collaboration with esteemed institutions such as the University of Cambridge, Imperial College London, and University College London. This latest round of investment will enable us to scale our operations and focus on the development of over 15 therapeutic programs currently in our portfolio, targeting critical areas such as oncology, major inflammatory disorders, and rare diseases. Our innovative model, combining a centralized team of drug development ‘architects’ and subject matter experts, allows us to rigorously evaluate and prioritize programs based on strong scientific hypotheses, ensuring that we de-risk initiatives early in the process and maximize our resources for greater capital efficiency. Funded by notable investors like Patient Square Capital, Rock Springs Capital, Reimagined Ventures, and UCL Technology Fund, we are poised to enhance our existing collaborations and forge new partnerships globally as we expand our operations in both Cambridge, UK, and Boston, USA. With this strategic funding, we are well-positioned to accelerate the clinical development of our lead programs and ultimately strive to deliver meaningful treatment options for patients in need. For more details on our groundbreaking work, visit us at www.apollotherapeutics.com.